Newsmax (NMAX) and Supercanal Sign Distribution Agreement

Deal Expands Newsmax's Footprint in the Caribbean Market

Newsmax Inc. (NYSE: NMAX) ("Newsmax" or the "Company"), through its subsidiary Newsmax Broadcasting, today announced that the Company has signed with Supercanal, one of the largest Caribbean independently owned broadcasters, to broadcast the Newsmax channel to three million Dominican Republic TV households.

The multi-year license deal will use groundbreaking AI to live dub Newsmax in Spanish, efficiently scaling the network's reach globally.

Newsmax now offers its popular U.S. channel in Latin America using neutral Spanish to enhance accessibility for viewers across the region, helping them stay informed with accurate, real-time translations of breaking news.

"Newsmax is excited about its partnership with Supercanal, who are committed to advancing innovative technology to expand access to trusted journalism," Andy Biggers, Newsmax's SVP of Distribution, said.

Biggers added, "Newsmax saw this agreement as both an opportunity to join with an innovative leader in the Dominican Republic, but also to strengthen America's ties with the country's people.

"The U.S. and the Dominican Republic have a long history of close political, economic, and social ties, and there is a large Dominican immigrant population in the U.S. Newsmax's entrance into the D.R. will strengthen ties between two democracies."

Marcos Jorge, Executive VP of Supercanal, said, "We are pleased to make Newsmax widely available in the Dominican Republic. Newsmax is a rising and respected news brand that will resonate in the Dominican Republic, especially with the content available in Spanish."

Newsmax will be available on channel 33.1 in the Dominican Republic.

Newsmax is fast becoming a global news brand, with the network having partnerships for distribution or licensing in over 100 countries across five continents.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Cytek faces $56M damages award in Beckman Coulter patent case
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall